👋 Hey, let’s get into it. What do AI drug discovery, Napster founder Sean Parker, and $1.3 billion have in common? Xaira Therapeutics.

After emerging from stealth two years ago with one of biotech's largest-ever launch financings and Parker among its high-profile backers, the AI drug discovery company has remained remarkably quiet. That's finally starting to change.

Xaira, whose first virtual cell model already queries 4.9 billion parameters, is now actively seeking partners that can contribute valuable preclinical datasets to strengthen its AI platform. Turns out when you've already raised $1.3 billion, the next competitive advantage isn't more money, it's more data.

💰 Vertex Buys Crinetics for $10B in Largest Acquisition in Company History
Vertex is making its biggest bet yet, agreeing to acquire Crinetics Pharmaceuticals for $10 billion. The deal adds newly approved acromegaly drug Palsonify, but executives appeared even more excited about investigational endocrine therapy atumelnant after what CEO Reshma Kewalramani called "floored us" Phase 2 data. Vertex believes the two assets could generate more than $5 billion in peak annual sales while establishing endocrine diseases as the fifth pillar of its business alongside cystic fibrosis, hematology, pain, and kidney disease. It's also the fourth biotech acquisition worth at least $10 billion this year.

🇨🇳 AstraZeneca Pays Up to $2.1B for Chinese COPD Challenger
AstraZeneca is doubling down on China, paying $200 million upfront and up to $1.9 billion in milestones for global rights outside China to Sino Biopharmaceutical's late-stage COPD candidate. The inhaled therapy is being positioned as a challenger to Merck's blockbuster hopeful Ohtuvayre, which generated $131 million during the first quarter alone. The agreement also deepens AstraZeneca's already massive investment in China's biotech ecosystem, where the company has committed roughly $15 billion across research, manufacturing, and partnerships.

💊 Kailera's Oral GLP-1 Delivers 11% Weight Loss in Phase 3 Trial
The race for effective obesity pills keeps getting tighter. Kailera Therapeutics announced its partner Hengrui Pharma's Phase 3 study showed its once-daily oral GLP-1 produced up to 11.1% weight loss after 50 weeks in adults with obesity or overweight. Those results are competitive with Eli Lilly's oral GLP-1 candidate. While Hengrui prepares regulatory filings in China, Kailera owns rights outside Greater China and is already advancing the therapy through a Phase 2 study. Another serious contender joins one of biotech's hottest markets.

🍄 Compass Reports Six-Month Durability for Phase 3 Psilocybin Depression Therapy
Compass Pathways strengthened its FDA case after new Phase 3 data showed patients with treatment-resistant depression maintained meaningful symptom improvements for six months following treatment with COMP360. Among patients who initially responded, nearly one-third eventually achieved remission despite entering the trial after depressive episodes lasting more than three years on average. Compass expects to complete its rolling FDA submission later this year and believes the psychedelic therapy could eventually generate peak annual sales of approximately $1.5 billion.

☎️ AI-Powered Business Calling Starting at $12/User
Easily manage users, intelligently monitor business interactions, and improve productivity with AI-powered business communications. Learn more

💉 Boehringer Licenses Viral Vector Platform for Cancer Vaccines
Boehringer Ingelheim secured exclusive rights to Prime Vector Technologies' ORFV platform to develop next-generation cancer vaccines.

💵 MeiraGTx Lands Up to $400M from Oberland Capital
The financing supports two late-stage gene therapies and provides mostly non-dilutive funding ahead of potential regulatory approvals.

✅ FDA Approves Vera's Trutakna for IgA Nephropathy
Vera's dual-target BAFF/APRIL therapy becomes the sixth FDA-approved IgA nephropathy treatment and the first to inhibit both disease-driving immune pathways, setting the stage for competition with Otsuka from Novartis.

📈 Kalohexis Files Confidential IPO for Obesity Pipeline
The Endevica spinout confidentially filed for an IPO to advance peptide therapies targeting obesity and cancer cachexia.

❌ Bristol Myers' Krazati Misses Phase 3 Colorectal Trial
Krazati failed both primary endpoints in a confirmatory colorectal cancer study, complicating Bristol Myers Squibb's path toward full FDA approval.

🏭 Evonik Invests $100M in Indiana API Manufacturing
Evonik will expand one of the world's largest active pharmaceutical ingredient facilities as U.S. demand for domestic CDMO capacity grows.

✌️ Tanabe Sells Manufacturing Business and 17 Drugs to Towa
Tanabe is offloading manufacturing operations and mature products to sharpen its focus on research, development, and business development.

🤝 Whitehawk and Biocytogen Partner on Five ADC Programs
Whitehawk will evaluate five bispecific antibody candidates from Biocytogen's platform for potential antibody-drug conjugate development.

Biotech funding is rebounding in 2026, but don't mistake that for an easy fundraising environment. Investors are writing massive checks again, yet most are flowing to later-stage companies with proven platforms or clear clinical catalysts. Early-stage startups are still finding capital much harder to come by. Here are the five biggest venture rounds of the first half of the year.

🥇 Isomorphic Labs — $2.1B
Alphabet's AI drug discovery company landed the second-largest biotech VC round ever despite not naming a single clinical candidate. Investors are betting its AlphaFold-powered platform can reshape how medicines are discovered.

🥈 NewLimit — $435M
The longevity startup is developing AI-designed therapies that reprogram aging cells to restore youthful function. Its lead mRNA candidate is expected to enter the clinic next year.

🥉 Beeline Medicines — $426.3M
Beeline emerged from stealth with immunology assets licensed from Bristol Myers Squibb and fresh backing from Bain Capital. Its lead lupus program is already in clinical testing.

4️⃣ Parabilis Medicines — $305M
Parabilis uses AI and physics-based modeling to design peptide drugs capable of targeting previously "undruggable" proteins. The company recently followed its financing with the largest biotech IPO in history.

5️⃣ Corxel Pharmaceuticals — $287M
Corxel rounds out the list with an oral GLP-1 candidate that recently reported encouraging mid-stage weight-loss data. Investors clearly believe the obesity market still has room for new winners.

One trend jumps off the page: AI shows up everywhere. Whether it's discovering drugs, designing proteins, or identifying new therapeutic targets, artificial intelligence has become one of biotech's favorite fundraising buzzwords. Somewhere, someone probably opened Claude once, added "AI-enabled" to their pitch deck, and accidentally raised a quarter-billion dollars.

📖 Read the full story

That's how many bottles of Amgen's heart failure drug Corlanor were voluntarily recalled after a foreign substance was discovered during manufacturing. The FDA classified the action as a Class II recall, meaning serious health consequences are considered unlikely, but it serves as another reminder that even routine manufacturing issues can quickly affect hundreds of thousands of medicines.

Here’s what biotech Redditors are talking about:

😵 I Hate My New Job...Three Weeks In
One Redditor wondered if they should quit after only three weeks at a small pharma company, citing nonexistent onboarding, conflicting instructions, overwhelming workloads, surprise travel requirements, and a manager who seemed too busy to answer basic questions. Most commenters agreed the bad management wasn't normal, but the chaos itself often is. Startups often mean wearing multiple hats, building processes from scratch, and figuring things out as you go. The real question is whether you're growing alongside the chaos or simply surviving it. Want more structure? Go to big pharma.

🎓 Should You Leave a Great Job to Pursue a PhD?
A young research associate making $93,000 at a biotech startup found themselves second-guessing everything after a retired mentor insisted they should leave immediately for graduate school. Reddit's verdict was refreshingly balanced. Many scientists shared success stories after working several years before pursuing a PhD, using that time to build savings, industry experience, and valuable technical skills. The consensus: if a PhD is part of your long-term plan, waiting isn't necessarily a mistake, as long as you're intentional about making those extra years count.

😳 Bryan Johnson Says His "Stomach Is Eating Itself"
The celebrity biohacker revealed he has incurable autoimmune gastritis, proving even the world's most optimized health routine can't out-hack every disease.

✂️ Novartis Cuts Another 322 Jobs in New Jersey
Novartis' fourth workforce reduction at its East Hanover campus brings total layoffs there to 572 employees, with roughly 800 expected by 2028.

🏢 Former Pfizer Headquarters Evacuated After Structural Scare
Buckling steel beams forced the evacuation of several Midtown Manhattan blocks as the former Pfizer headquarters undergoes conversion into apartments.

💉 Employers Still Say "No" to GLP-1 Weight-Loss Coverage
Most employer health plans still refuse to cover GLP-1 obesity drugs, with many limiting reimbursement to diabetes despite growing medical indications.

🧬 Replicate Bioscience Wants RNA Medicines to Go the Distance
Most mRNA therapies produce proteins for only a limited time before fading out. Replicate Bioscience is betting self-replicating RNA can change that. Its platform uses engineered RNA that temporarily copies itself inside cells, dramatically increasing protein production while requiring much smaller doses than conventional mRNA therapies. The company is applying the technology across cancer, infectious diseases, and autoimmune disorders, hoping to expand RNA therapeutics far beyond vaccines and into chronic diseases.

🧠 July 9, 1933: The Doctor Who Turned Diseases Into Stories Is Born
Few physicians have done more to humanize neuroscience than Dr. Oliver Sacks. Born on this day in 1933, the British-American neurologist became famous for books like Awakenings and The Man Who Mistook His Wife for a Hat, transforming complex neurological disorders into deeply personal stories about the people living with them. His work reminded generations of physicians that every diagnosis comes with a human being behind it, a lesson that's just as relevant in today's AI-driven era of medicine.

Thinking back to the opening story… Napster changed how we consume music. Xaira wants to change how we discover drugs. Sean Parker has somehow found himself in both revolutions. And there’s a greater-than-zero chance someone in a Xaira meeting has already described it as “the Napster of biotech.”

That’s all for today. See you Tuesday for the next issue. 👋

✍️ Today’s email was brought to you by Josh Martin.

If you’re enjoying BioNucleus, share it with a friend or coworker who’d get value from it. We’re a small operation, and every share makes a bigger difference than you think.

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead

BioNucleus Briefing lands in the inboxes of 1,200+ scientists, founders, investors, operators, and industry decision-makers twice a week.

If you'd like to sponsor a future issue, just hit reply and let's talk.